|
Moderna shares more than doubled Wednesday after it announced
initial results from a study of an experimental cancer treatment
that would be the first of its kind if approved by regulators.
Moderna and Merck are developing a treatment using an mRNA-based
cancer vaccine called intismeran that is designed to be tailored
to individual patients based on unique mutations within their
tumors. In current studies, they are pairing it with Keytruda, a
immunotherapy drug made by Merck.
The study compared using intismeran and Keytruda together on
melanoma patients against using Keytruda alone. The companies
said patients who received the combination lived longer without
cancer returning or metastasizing than patients who got Keytruda
alone.
The companies did not say how long patients survived without
cancer returning or whether patients lived longer overall. They
said they plan to present the study results at an upcoming
international medical meeting.
Moderna shares rose more than 120% to $140.12 a share. Merck
shares rose about 11%.
All contents © copyright 2026 Associated Press. All rights reserved
|
